These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21299254)

  • 1. Pleiotropic effects of sevelamer beyond phosphate binding in end-stage renal disease patients: a randomized, open-label, parallel-group study.
    Lin YF; Chien CT; Kan WC; Chen YM; Chu TS; Hung KY; Tsai TJ; Wu KD; Wu MS
    Clin Drug Investig; 2011; 31(4):257-67. PubMed ID: 21299254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis.
    Takei T; Otsubo S; Uchida K; Matsugami K; Mimuro T; Kabaya T; Akiba T; Nitta K
    Nephron Clin Pract; 2008; 108(4):c278-83. PubMed ID: 18434749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.
    Evenepoel P; Selgas R; Caputo F; Foggensteiner L; Heaf JG; Ortiz A; Kelly A; Chasan-Taber S; Duggal A; Fan S
    Nephrol Dial Transplant; 2009 Jan; 24(1):278-85. PubMed ID: 18820280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
    Chen N; Wu X; Ding X; Mei C; Fu P; Jiang G; Li X; Chen J; Liu B; La Y; Hou F; Ni Z; Fu J; Xing C; Yu X; Huang C; Zuo L; Wang L; Hunter J; Dillon M; Plone M; Neylan J
    Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis.
    Goldsmith DR; Scott LJ; Cvetković RS; Plosker GL
    Drugs; 2008; 68(1):85-104. PubMed ID: 18081374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.
    Brandenburg VM; Schlieper G; Heussen N; Holzmann S; Busch B; Evenepoel P; Vanholder R; Meijers B; Meert N; Fassbender WJ; Floege J; Jahnen-Dechent W; Ketteler M
    Nephrol Dial Transplant; 2010 Aug; 25(8):2672-9. PubMed ID: 20172849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.
    Slatopolsky EA; Burke SK; Dillon MA
    Kidney Int; 1999 Jan; 55(1):299-307. PubMed ID: 9893140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
    Ahmadi F; Shamekhi F; Lessan-Pezeshki M; Khatami MR
    Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):934-8. PubMed ID: 22982903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease.
    Rastogi A
    Ther Adv Cardiovasc Dis; 2013 Dec; 7(6):322-42. PubMed ID: 24327730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
    Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients.
    Hamida FB; Fatma LB; Barbouch S; Kaaroud H; Helal I; Hedri H; Abdallah TB; Maiz HB; Kheder A
    Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):183-8. PubMed ID: 18310864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of sevelamer hydrochloride in patients with end-stage renal disease: a retrospective study.
    Alam S; Hussain A; Daiwajna R; Tan J
    Singapore Med J; 2013 May; 54(5):263-6. PubMed ID: 23716151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial.
    Garg JP; Chasan-Taber S; Blair A; Plone M; Bommer J; Raggi P; Chertow GM
    Arthritis Rheum; 2005 Jan; 52(1):290-5. PubMed ID: 15641045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability.
    de Francisco AL; Leidig M; Covic AC; Ketteler M; Benedyk-Lorens E; Mircescu GM; Scholz C; Ponce P; Passlick-Deetjen J
    Nephrol Dial Transplant; 2010 Nov; 25(11):3707-17. PubMed ID: 20530499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term efficacy of sevelamer versus calcium acetate in patients with chronic kidney disease stage 3-4.
    Gulati A; Sridhar V; Bose T; Hari P; Bagga A
    Int Urol Nephrol; 2010 Dec; 42(4):1055-62. PubMed ID: 20020207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study.
    Locatelli F; Spasovski G; Dimkovic N; Wanner C; Dellanna F; Pontoriero G
    Nephrol Dial Transplant; 2014 May; 29(5):1061-73. PubMed ID: 24302608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis.
    Ketteler M; Rix M; Fan S; Pritchard N; Oestergaard O; Chasan-Taber S; Heaton J; Duggal A; Kalra PA
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1125-30. PubMed ID: 18450923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients.
    Liu YL; Lin HH; Yu CC; Kuo HL; Yang YF; Chou CY; Lin PW; Liu JH; Liao PY; Huang CC
    Ren Fail; 2006; 28(8):701-7. PubMed ID: 17162430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy, safety and anti-inflammatory activity of two sevelamer tablet forms in patients on low-flux hemodialysis.
    Tzanno-Martins C; Biavo BM; Ferreira-Filho O; Ribeiro-Junior E; João-Luiz MV; Degaspari S; Scavone C; Kawamoto E
    Int J Immunopathol Pharmacol; 2014; 27(1):25-35. PubMed ID: 24674676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.